Gary A Herman

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Curr Med Res Opin 22:1939-47. 2006
  2. ncbi request reprint Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist
    Ronda K Rippley
    Clinical Drug Metabolism, WP75B 100, PO Box 4, Merck Research Laboratories, West Point, PA 19486 0004, USA
    J Clin Pharmacol 47:323-33. 2007
  3. ncbi request reprint Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses
    Gary A Herman
    Merck and Co, Whitehouse Station, NJ 07065, USA
    Clin Pharmacol Ther 78:675-88. 2005
  4. ncbi request reprint Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects
    Gary A Herman
    Merck Research Laboratories, RY34 A536, 126 East Lincoln Avenue, Rahway, NJ 07065 0900, USA
    J Clin Pharmacol 46:876-86. 2006
  5. ncbi request reprint Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Experimental Medicine, Rahway, New Jersey 07065, USA
    J Clin Endocrinol Metab 91:4612-9. 2006
  6. ncbi request reprint Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
    Arthur Bergman
    Merck and Co Inc, Whitehouse Station, NJ 07065, USA
    Biopharm Drug Dispos 28:307-13. 2007
  7. ncbi request reprint Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers
    Arthur J Bergman
    Merck and Co, Inc, Whitehouse Station, New Jersey 07065 0900, USA
    Clin Ther 28:55-72. 2006
  8. ncbi request reprint Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
    Stella H Vincent
    Merck Research Laboratories, RY 80 141, P O Box 2000, Rahway, NJ 07065, USA
    Drug Metab Dispos 35:533-8. 2007
  9. ncbi request reprint Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin
    Elizabeth M Migoya
    Merck Research Laboratories, Rahway, NJ, USA
    Can J Clin Pharmacol 16:e165-70. 2009
  10. pmc Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
    Goutam C Mistry
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    Br J Clin Pharmacol 66:36-42. 2008

Detail Information

Publications19

  1. ncbi request reprint Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Curr Med Res Opin 22:1939-47. 2006
    ....
  2. ncbi request reprint Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist
    Ronda K Rippley
    Clinical Drug Metabolism, WP75B 100, PO Box 4, Merck Research Laboratories, West Point, PA 19486 0004, USA
    J Clin Pharmacol 47:323-33. 2007
    ....
  3. ncbi request reprint Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses
    Gary A Herman
    Merck and Co, Whitehouse Station, NJ 07065, USA
    Clin Pharmacol Ther 78:675-88. 2005
    ....
  4. ncbi request reprint Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects
    Gary A Herman
    Merck Research Laboratories, RY34 A536, 126 East Lincoln Avenue, Rahway, NJ 07065 0900, USA
    J Clin Pharmacol 46:876-86. 2006
    ....
  5. ncbi request reprint Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Experimental Medicine, Rahway, New Jersey 07065, USA
    J Clin Endocrinol Metab 91:4612-9. 2006
    ..The degree of DPP-4 inhibition and the level of active incretin augmentation required for glucose lowering efficacy after an oral glucose tolerance test (OGTT) were evaluated...
  6. ncbi request reprint Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
    Arthur Bergman
    Merck and Co Inc, Whitehouse Station, NJ 07065, USA
    Biopharm Drug Dispos 28:307-13. 2007
    ..5% pooled across doses) and renal clearance (344 ml/min pooled across doses) were not statistically significant. Sitagliptin was generally well tolerated at all the doses evaluated...
  7. ncbi request reprint Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers
    Arthur J Bergman
    Merck and Co, Inc, Whitehouse Station, New Jersey 07065 0900, USA
    Clin Ther 28:55-72. 2006
    ..Sitagliptin is an orally active and selective DPP-IV inhibitor currently in Phase III development for the treatment of type 2 diabetes mellitus...
  8. ncbi request reprint Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
    Stella H Vincent
    Merck Research Laboratories, RY 80 141, P O Box 2000, Rahway, NJ 07065, USA
    Drug Metab Dispos 35:533-8. 2007
    ..CYP3A4 was the major cytochrome P450 isozyme responsible for the limited oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8...
  9. ncbi request reprint Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin
    Elizabeth M Migoya
    Merck Research Laboratories, Rahway, NJ, USA
    Can J Clin Pharmacol 16:e165-70. 2009
    ..Sitagliptin is primarily excreted by renal elimination as unchanged drug, with only a small percentage (approximately 16%) undergoing hepatic metabolism...
  10. pmc Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
    Goutam C Mistry
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    Br J Clin Pharmacol 66:36-42. 2008
    ..Since both agents may potentially be co-administered, the purpose of this study was to examine the effects of sitagliptin on glyburide pharmacokinetics...
  11. pmc Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males
    Gary A Herman
    Merck, Whitehouse Station, NJ Radiant Research, Honolulu, HI, USA
    Br J Clin Pharmacol 71:429-36. 2011
    ..The present aim was to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety characteristics of sitagliptin following single doses in healthy, young Japanese males...
  12. doi request reprint Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
    Goutam C Mistry
    Merck Research Laboratories, RY34 A400, 126 East Lincoln Avenue, Rahway, NJ 07065, USA
    J Clin Pharmacol 48:592-8. 2008
    ....
  13. ncbi request reprint Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects
    Goutam C Mistry
    Merck Research Laboratories, Mail Code RY34 A536, PO Box 2000, Rahway, NJ 07065 0900, USA
    J Clin Pharmacol 47:159-64. 2007
    ..98 (0.93, 1.02) and 0.99 (0.88, 1.12), respectively. In conclusion, sitagliptin did not alter the pharmacokinetics of rosiglitazone in healthy subjects...
  14. ncbi request reprint Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
    Arthur J Bergman
    Merck Research Laboratories, P O Box 4, WP75B 100, West Point, PA 19486, USA
    Diabetes Care 30:1862-4. 2007
  15. doi request reprint A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects
    Daniel M Bloomfield
    Merck and Company Inc, Whitehouse Station, New Jersey, USA
    J Clin Pharmacol 49:937-46. 2009
    ..In conclusion, at clinically relevant concentrations, sitagliptin is not associated with clinically meaningful QTcf prolongation...
  16. doi request reprint Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin
    D Hamish Wright
    Department of Clinical Pharmacology, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, NJ 07065, USA
    J Clin Pharmacol 49:1157-67. 2009
    ....
  17. doi request reprint Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure
    Rhonda Kaufman
    Department of Experimental Medicine, Merck Research Laboratories, Merck Sharp and Dohme Corp, Rahway, New Jersey 07065 0900, USA
    J Am Soc Hypertens 4:311-8. 2010
    ..Differences from placebo were statistically significant except for losartan 100 mg. AIx is a good biomarker of acute hemodynamic effects of nitric oxide in prehypertensive/Stage 1 hypertension...
  18. doi request reprint The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake
    Carol Addy
    Merck Research Laboratories, Boston, MA 02115, USA
    Cell Metab 7:68-78. 2008
    ..Mechanism-of-action studies suggest that engagement of the CB1R by taranabant leads to weight loss by reducing food intake and increasing energy expenditure and fat oxidation...
  19. ncbi request reprint Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Markolf Hanefeld
    GWT Technical University, Dresden, Germany
    Curr Med Res Opin 23:1329-39. 2007
    ..Additionally, the glycemic response to sitagliptin 100 mg daily was evaluated as a once-daily (100 mg once-daily) or twice-daily (50 mg twice-daily) dosing regimen...